Eli Lilly and Company (NYSE:LLY) is one of Goldman Sachs’ top healthcare stock picks. On July 9, the company confirmed the ...

Eli Lilly's weight loss drugs, especially Zepbound and Mounjaro, have driven impressive revenue growth. Click here to read an ...

Eli Lilly (LLY) has won Health Canada approval for Omvoh (mirikizumab) in patients with Crohn’s disease, the company said on ...

The Eli Lilly and Company Foundation awarded a multi-year grant of up to $5.5 million to the Indianapolis Public Schools (IPS ...

Eli Lilly's LLY -0.28% Get Free Report short percent of float has fallen 3.96% since its last report. The company recently reported that it has 7.71 million shares sold short, which is 0.97% of all ...

NVO shares fall 19.9% year to date amid weak CagriSema data, CEO exit and rising pressure from rivals in obesity care.

The initiative is a significant boost to STEM programming that IPS has sought to expand through its reorganization plan known ...

Eli Lilly (LLY) closed the most recent trading day at $771.75, moving -3.45% from the previous trading session. The stock trailed the S&P 500, which registered a daily loss of 0.4%. Meanwhile, the Dow ...

Lilly Endowment Community Scholarship application is now available in Carroll County through the. The Lilly Endowment Community Scholarship Program (LECSP) will provide 147 scholarships ...

Endometrial Cancer is a type of cancer that begins in the lining of the uterus, most commonly affecting postmenopausal women. Rising prevalence due to increasing obesity rates and aging population, ...

For adults with obesity treated with once-weekly tirzepatide, cardiometabolic risk factor improvements were positively ...

Omvoh® is now indicated for both major forms of Inflammatory Bowel Disease (IBD) – ulcerative colitis (UC) and Crohn’s ...